OncoMatch/Clinical Trials/NCT04680260
OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer
Is NCT04680260 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for colorectal cancer.
A study investigating if analysis of circulating tumor DNA (ctDNA) can guide adjuvant treatment in patients with advanced colorectal cancer (CRC)
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
absolute neutrophil count ≥1.5x109/l and thrombocytes ≥ 100x109/l
Kidney function
calculated or measured renal glomerular filtration rate at least 30 ml/min
Liver function
bilirubin ≤ 1.5 x upper normal value and alanine aminotransferase ≤ 3 x upper normal value
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04680260 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages